The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial

Redox Report

Volumn 21, Issue 1, 2016, Pages 14-23

  Zhang, Lei ^a,b   Coombes, Jeff ^a   Pascoe, Elaine M ^a   Badve, Sunil V ^a,c   Dalziel, Kim ^d   Cass, Alan ^a,e   Clarke, Philip ^d   Ferrari, Paolo ^a,f   McDonald, Stephen P ^a,g   Morrish, Alicia T ^a   Pedagogos, Eugenie ^a,h   Perkovic, Vlado ^a,i   Reidlinger, Donna ^a   Scaria, Anish ^a   Walker, Rowan ^a,j   Vergara, Liza A ^a   Hawley, Carmel M ^a,c,k   Johnson, David W ^a,c,k  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b GUANGDONG PROVINCIAL HOSPITAL OF CHINESE MEDICINE   (China)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^f FREMANTLE HOSPITAL   (Australia)

^g UNIVERSITY OF ADELAIDE   (Australia)

^h ROYAL MELBOURNE HOSPITAL   (Australia)

ⁱ George Institute   (Australia)

^j ALFRED HOSPITAL   (Australia)

^k TRANSLATIONAL RESEARCH INSTITUTE   (Australia)

more..

Author keywords

Anaemia; Chronic kidney disease; Erythropoiesis stimulating agent; Oxidative stress; Pentoxifylline

Indexed keywords

CARBONYL DERIVATIVE; FERRITIN; GLUTATHIONE PEROXIDASE; HEMOGLOBIN; ISOPROSTANE DERIVATIVE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PENTOXIFYLLINE; PLACEBO; RECOMBINANT ERYTHROPOIETIN; SUPEROXIDE DISMUTASE; TRANSFERRIN;

AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG TREATMENT FAILURE; ENZYME ACTIVITY; ERYTHROPOIESIS; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; OXIDATIVE STRESS; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RETICULOCYTE COUNT; SYSTOLIC BLOOD PRESSURE; TRANSFERRIN BLOOD LEVEL; TREATMENT OUTCOME;

EID: 84978699362     PISSN: 13510002     EISSN: 17432928     Source Type: Journal    
DOI: 10.1179/1351000215Y.0000000022     Document Type: Article

References (33)

1. M.Stauffer, T.Fan. Prevalence of anemia in chronic kidney disease in the United States. PLoS One 2014;9(1):e84943.
2. Kdoqi. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007;50(3):471–530.
3. S.C.Hung, Y.P.Lin, D.C.Tarng. Erythropoiesis-stimulating agents in chronic kidney disease: what have we learned in 25 years? J Formos Med Assoc 2014;113(1):3–10.
4. S.D.Solomon, H.Uno, E.F.Lewis, K.U.Eckardt, J.Lin, E.A.Burdmann, Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 2010;363(12):1146–55.
5. J.Smrzova, J.Balla, P.Barany. Inflammation and resistance to erythropoiesis-stimulating agents–what do we know and what needs to be clarified? Nephrol Dial Transplant2005;20(Suppl. 8):viii2–7.
6. F.Locatelli, B.Canaud, K.U.Eckardt, P.Stenvinkel, C.Wanner, C.Zoccali. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 2003;18(7):1272–80.
7. P.Stenvinkel. Anaemia and inflammation: what are the implications for the nephrologist? Nephrol Dial Transplant 2003;18(Suppl. 8):viii17–22.
8. E.Tutal, S.Sezer, A.Bilgic, D.Aldemir, S.Turkoglu, O.Demirel, Influence of oxidative stress and inflammation on rHuEPO requirements of hemodialysis patients with CRP values ‘in normal range’. Transplant Proc 2007;39(10):3035–40.
9. D.W.Johnson, E.M.Pascoe, S.V.Badve, K.Dalziel, A.Cass, P.Clarke, A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the handling erythropoietin resistance with oxpentifylline (HERO) trial. Am J Kidney Dis 2015;65(1):49–57.
10. C.M.Iain,, Cooper AC. Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant 2002;17(Suppl. 11):39–43.
11. A.Cooper, A.Mikhail, M.Lethbridge, D.Kemeny, I.Macdougall. Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure. J Am Soc Nephrol 2004;15(7):1877–82.
12. A.Mohammadpour, F.Nazemian, M.Khaiat, M.Tafaghodi, P.Salari, S.Charkazi, Evaluation of the effect of pentoxifylline on erythropoietin-resistant anemia in hemodialysis patients. Saudi J Kidney Dis Transpl 2014;25(1):73–8.
13. D.W.Johnson, C.M.Hawley, B.Rosser, E.Beller, C.Thompson, R.G.Fassett, Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial. BMC Nephrol 2008;9:8.
14. D.Briskey, G.Wilson, R.Fassett, J.Coombes. Optimized method for quantification of total F(2)-isoprostanes using gas chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2014;90:161–6.
15. R.Levine, D.Garland, C.Oliver, A.Amici, I.Climent, A.Lenz, Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 1990;186:464–78.
16. M.Madesh, K.Balasubramanian. Microtiter plate assay for superoxide dismutase using MTT reduction by superoxide. Indian J Biochem Biophys 1998;35(3):184–8.
17. C.Wheeler, J.Salzman, N.Elsayed, S.Omaye, D.J.Korte. Automated assays for superoxide dismutase, catalase, glutathione peroxidase, and glutathione reductase activity. Anal Biochem 1990;184(2):193–9.
18. S.Roger, B.Cooper. What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials? Nephrology (Carlton) 2004;9(4):223–8.
19. D.W.Johnson, E.M.Pascoe, S.V.Badve, K.Dalziel, A.Cass, P.C.BEc, A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance with Oxpentifylline (HERO) trial. Am J Kidney Dis 2015;65(1):49–57.
20. B.P.Oberg, E.McMenamin, F.L.Lucas, E.McMonagle, J.Morrow, T.A.Ikizler, Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004;65(3):1009–16.
21. L.F.Ramos, A.Shintani, T.A.Ikizler, J.Himmelfarb. Oxidative stress and inflammation are associated with adiposity in moderate to severe CKD. J Am Soc Nephrol 2008;19(3):593–9.
22. G.J.Handelman, M.F.Walter, R.Adhikarla, J.Gross, G.E.Dallal, N.W.Levin, Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int 2001;59(5):1960–6.
23. I.Wiswedel, D.Peter, A.Gardemann, F.Carluccio, H.Hampl, W.Siems. Serum concentrations of F2-isoprostanes and 4-hydroxynonenal in hemodialysis patients in relation to inflammation and renal anemia. Biomark Insights 2008;3:419–28.
24. H.F.Tbahriti, A.Kaddous, M.Bouchenak, K.Mekki. Effect of different stages of chronic kidney disease and renal replacement therapies on oxidant-antioxidant balance in uremic patients. Biochem Res Int 2013;2013:358985.
25. P.R.Aveles, C.R.Criminacio, S.Goncalves, A.T.Bignelli, L.M.Claro, S.S.Siqueira, Association between biomarkers of carbonyl stress with increased systemic inflammatory response in different stages of chronic kidney disease and after renal transplantation. Nephron Clin Pract 2010;116(4):c294–9.
26. B.A.Zachara, J.Gromadzińska, W.Wąsowicz, Z.Zbróg. Red blood cell and plasma glutathione peroxidase activities and selenium concentration in patients with chronic kidney disease: a review. Acta Biochim Pol 2006;53(4):663–77.
27. S.Iasioli, R.Schiavon, L.Petrosino, L.Cavallini, E.De Fanti, A.Zambello, Do different dialytic techniques have different atherosclerotic and antioxidant activities? ASAIO J 2001;47(5):516–21.
28. M.Gallucci, R.Lubrano, C.Meloni, M.Morosetti, S.Manca di Villahermosa, P.Scoppi, Red blood cell membrane lipid peroxidation and resistance to erythropoietin therapy in hemodialysis patients. Clin Nephrol 1999;52(4):239–45.
29. H.B.Suliman, M.Ali, C.A.Piantadosi. Superoxide dismutase-3 promotes full expression of the EPO response to hypoxia. Blood 2004;104(1):43–50.
30. A.Rusu, F.Rusu, D.Zalutchi, A.Muresan, M.Gherman Caprioara, I.Kacso. The influence of vitamin E supplementation on erythropoietin responsiveness in chronic hemodialysis patients with low levels of erythrocyte superoxide dismutase. Int Urol Nephrol 2013;45(2):495–501.
31. V.Deved, P.Poyah, M.T.James, M.Tonelli, B.J.Manns, M.Walsh, Ascorbic acid for anemia management in hemodialysis patients: a systematic review and meta-analysis. Am J Kidney Dis 2009;54(6):1089–97.
32. M.Kamgar, F.Zaldivar, N.Vaziri, M.Pahl. Antioxidant therapy does not ameliorate oxidative stress and inflammation in patients with end-stage renal disease. J Natl Med Assoc 2009;101(4):336–44.
33. J.Himmelfarb, S.Phinney, T.A.Ikizler, J.Kane, E.McMonagle, G.Miller. Gamma-tocopherol and docosahexaenoic acid decrease inflammation in dialysis patients. J Ren Nutr 2007;17(5):296–304.